A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
about
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and SimulationsOptoDyCE as an automated system for high-throughput all-optical dynamic cardiac electrophysiology.Automated Algorithm for J-Tpeak and Tpeak-Tend Assessment of Drug-Induced Proarrhythmia RiskHierarchical Bayesian inference for ion channel screening dose-response dataEarly assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.Systems Toxicology: Real World Applications and Opportunities.Period doubling cascades of limit cycles in cardiac action potential models as precursors to chaotic early Afterdepolarizations.Proarrhythmic and Torsadogenic Effects of Potassium Channel Blockers in Patients.Human Engineered Heart Tissue: Analysis of Contractile ForceA new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells.Computational cardiology and risk stratification for sudden cardiac death: one of the grand challenges for cardiology in the 21st century.Characterizing QT interval prolongation in early clinical development: a case study with methadone.Induced pluripotent stem-cell-derived cardiomyocytes: cardiac applications, opportunities, and challenges.Opportunities to Apply the 3Rs in Safety Assessment Programs.FutureTox III: Bridges for Translation.Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening.Commentary on R&D Trends Away from General Medicine/Cardiovascular Drugs: Can the FDA Help Reverse the Trend?The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.Pharmacokinetic-pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studies.Human ex-vivo action potential model for pro-arrhythmia risk assessment.Temperature Effects on Kinetics of KV11.1 Drug Block Have Important Consequences for In Silico Proarrhythmic Risk Prediction.A temperature-dependent in silico model of the human ether-à-go-go-related (hERG) gene channel.Quantitative Comparison of Effects of Dofetilide, Sotalol, Quinidine, and Verapamil between Human Ex vivo Trabeculae and In silico Ventricular Models Incorporating Inter-Individual Action Potential Variability.Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk AssessmentMechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer Therapeutics.Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?Novel Two-Step Classifier for Torsades de Pointes Risk Stratification from Direct Features.Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.Evaluation of Optogenetic Electrophysiology Tools in Human Stem Cell-Derived Cardiomyocytes.In Vitro and In Silico Risk Assessment in Acquired Long QT Syndrome: The Devil Is in the Details.Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for in Silico Proarrhythmia Risk Assessment.Adult Human Primary Cardiomyocyte-Based Model for the Simultaneous Prediction of Drug-Induced Inotropic and Pro-arrhythmia Risk.Global Optimization of Ventricular Myocyte Model to Multi-Variable Objective Improves Predictions of Drug-Induced Torsades de Pointes.Composite Biomarkers Derived from Micro-Electrode Array Measurements and Computer Simulations Improve the Classification of Drug-Induced Channel Block.Beyond drug-drug interactions: effects of transporter inhibition on endobiotics, nutrients and toxins.Observations on conducting whole-cell patch clamping of the hERG cardiac K+ channel in pure human serum.Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations.Recent developments in the science of proarrhythmic cardiac safety of new drugs.Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
P2860
Q26739743-0D0696A3-B741-45C1-B927-3A8FD57A0FEAQ27317028-4DB9BD91-B938-4F5A-9F58-5194BB36FAE6Q28468489-D08BDF69-0377-4F07-8429-5A8DA131CC8CQ28590540-5635BCEB-EF12-459A-A7B5-E9118A8CC445Q31140927-BF64DBC3-9AC7-4225-9416-CBAE3859AFFEQ33577370-85F9B808-AABD-4A59-9F90-270E5575B2EFQ36335018-C71C0712-8341-4CB4-8F82-5143B8F7843DQ36970774-469B4384-5695-4F55-8AE8-2F2DD2806CB2Q37094032-D4D92FA9-39A0-4973-AC1C-0978FBCEF7C1Q37228986-7C23DF01-0A7B-4852-8FA1-65F1F6C77677Q37466831-52BA5D29-CFB2-47F4-8E46-3F14486616C3Q38735144-D7A90122-01E5-4247-8119-C87661386B34Q38738472-B11FECD6-9DB3-4D10-8803-4E3C9B63E525Q38774773-BCA5FAE4-2F1C-4DE3-B4DB-E23D6157006FQ38805551-5BDE0D46-E391-40D8-81B2-DFB06CD360ACQ38819976-89145028-E120-42C0-94FE-D01BF9E854D8Q39050993-DDBC82B7-B921-43A6-9675-080EA874A707Q39388070-6F3EC459-0C2E-483E-8E2A-428010C3DC78Q39398161-1F47FE5D-62E2-4731-A4D8-E30B82949371Q39592121-0F823265-3632-4319-8D94-48E1D6507466Q39729113-8A3D25EE-9102-4ABC-BC61-DF904BFD748FQ39758131-D75E03F2-DD06-44E9-A2D8-1C246893F9AEQ39767396-497E556E-CB6F-442B-A0E2-EC78805A03CEQ41463131-EB9D4ADE-DF8D-45BF-86BE-A08EC8554984Q41524806-93CFE07D-E3A5-4952-9048-7FDC80C4DFBFQ41688591-08B64C1A-38A1-4685-AE52-9BD9173DD8C4Q42361494-D65BD1F8-686D-4135-8F9F-0856A33E09F5Q45943493-2D0F3D9B-14AF-4CFC-A9CB-078A7E6EDA90Q45981926-1C64C707-0C3B-495C-A9B1-100C3525FD2CQ46086758-9FC71902-3F98-4719-B136-C1A88B0750CCQ47095257-61B97B83-6769-450D-8DA9-579CC4826227Q47162110-54BE1FF3-8CA2-466A-B597-20829F0C0690Q47194598-FD482762-57FF-494D-B8A2-24C905A791D6Q47194629-7883416C-D957-4D97-988E-247EE63B85FAQ47558343-D7BC9EC7-1731-40E4-B4DC-EC9BD9FFA2DAQ47895958-CC8E074B-00E8-4003-869D-B9F0966C204EQ48017483-280AF25B-452A-4D60-880D-CBC9BF8CF80FQ49957155-F25E0769-0118-41F9-9789-ABA56912E3E1Q50665549-C941D89F-B01A-43F3-A000-B28A50AB3126Q51146786-D338D01D-BE14-4078-A873-3C2AA5B3DD67
P2860
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A New Perspective in the Field ...... Proarrhythmia Assay Paradigm.
@en
type
label
A New Perspective in the Field ...... Proarrhythmia Assay Paradigm.
@en
prefLabel
A New Perspective in the Field ...... Proarrhythmia Assay Paradigm.
@en
P2093
P2860
P356
P1476
A New Perspective in the Field ...... o Proarrhythmia Assay Paradigm
@en
P2093
Anders Lindqvist
Bruce Damiano
Carlos A Obejero-Paz
David G Strauss
David Rampe
Gary Gintant
Gul Erdemli
James Kramer
John Imredy
John Koerner
P2860
P356
10.1177/1087057115594589
P577
2015-07-13T00:00:00Z